Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may guide chemo decisions for advanced breast cancer

NCT ID NCT01349842

Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring circulating tumor cells (CTCs) in the blood can help doctors decide when to switch chemotherapy for women with metastatic breast cancer that has worsened after two prior treatments. The trial involved 265 women and compared standard care with CTC-guided treatment decisions. The goal was to see if this approach improves overall survival and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

265 people

The number who actually took part.

Started

Mar 2010

Finished

Nov 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women over the age of 18 years. * WHO performance status: 0 to 4. * Metastatic breast cancer. * Progression after 2 lines of chemotherapy with decision to initiate third-line chemotherapy. * Disease evaluable by CTC (CTC-positive before starting chemotherapy). * Histology: lobular or ductal adenocarcinoma. * Information of the patient and signature of the informed consent form by the patient or her legal representative. Exclusion Criteria: * Disease not evaluable by CTC (CTC-negative before starting chemotherapy). * History of other potentially metastatic cancer (stage III or IV cancer) different from breast cancer. * Histology other than lobular or ductal adenocarcinoma. * Pregnant woman, women likely to become pregnant or nursing mothers. * Persons deprived of their freedom or under guardianship. * Women unable to comply with the medical follow-up of the study for geographical, social or mental reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer ductal infiltrating metastatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast carcinoma invasive ductal breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer ductal infiltrating metastatic

Contacts and locations

Locations

  • Centre Georges Francois Leclerc

    Dijon, 21079, France

  • Chu Limoges

    Limoges, 87042, France

  • Clinique Victor Hugo

    Le Mans, 72000, France

  • Hopital Saint Louis

    Paris, 75475, France

  • Institut Curie

    Paris, 75005, France

  • Institut Rene Huguenin Curie

    Saint-Cloud, 92210, France

  • Institut de Canacerologie de L'Ouest

    Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.